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Lynch syndrome (LS) is characterized by an autosomal dominant inheritance of the early onset of colorectal cancer (CRC) and
endometrial cancer, as well as increased risk for several other cancers including gastric, urinary tract, ovarian, small bowel, biliary
tract, and brain tumors. The syndrome is due to a mutation in one of the four DNA mismatch repair (MMR) genes MLH1, MSH2,
MSH6,o rPMS2. The majority of LS patients and families can now be identiﬁed, and the underlying mutation detected using
genetic diagnostics. Regular surveillance for CRC and endometrial cancer has proved beneﬁcial for mutation carriers. However,
screening for other tumors is also recommended even though experiences in the screening of these tumors is limited. Prophylactic
colectomy, prophylactic hysterectomy, and bilateral salpingo-oophorectomy may be reasonable options for selected patients with
LS. This paper describes the features and management of LS.
1.Introduction
Lynch syndrome (LS), also referred to as hereditary non-
polyposis colorectal cancer (HNPCC), is the most common
form of hereditary colorectal cancer, accounting for 2–5% of
all colorectal cancer (CRC) cases [1, 2]. The cancer predispo-
sition in LSarises fromgermlinemutations inanyofthefour
DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6,
or PMS2 [3]. The mutation carriers are at high risk for devel-
oping CRC and endometrial cancer at a young age [4]. Many
other tumor types such as gastric, ovarian, small bowel, uri-
nary,andbiliarytract,aswellasbraintumors,havealsobeen
associated with LS [5, 6].
Clinical criteria, known as Amsterdam criteria I and II,
have served to identify in LS families [7, 8]. Knowledge of the
molecular genetic background of this syndrome has made
it possible to develop molecular diagnostic methods, such
asmicrosatelliteinstability(MSI)andimmunohistochemical
analysis, to identify cases with LS [9, 10]. Identiﬁcation of
thesehigh-riskindividualsisnecessarysothatscreeningpro-
gramscanbeinitiatedtopreventthedevelopmentofcancers.
Screening for colorectal and endometrial cancers has proved
beneﬁcial for mutation carriers of LS [11, 12]. Obtaining
more data on the features and behavior of diﬀerent tumors
associated with LS is also important in order to develop the
management of these tumors.
This paper reviews the clinicopathological features, diag-
nostic criteria, and management of LS.
2.GeneticCharacteristicsofLynchSyndrome
Mutations in four DNA mismatch repair (MMR) genes,
MLH1, MSH2, PMS2,a n dMSH6, are known to cause sus-
ceptibility to LS [3]. The main function of MMR is to main-
tain genomic stability by correcting mismatches generated
during DNA replication. MMR malfunction results in a mu-
tator phenotype and microsatellite instability (MSI). In mu-
tationcarrierswithLynchsyndrome,onemutationispresent
in each copy of the gene inherited via the germline and is
therefore present in all cells. Only one other mutation (so-
matic) is required for the development of cancer. Approxi-
mately 95% of mutations reported so far in LS families have
been the MLH1, MSH2,o rMSH6 genes [13].
MSI is a hallmark of tumors in LS, but is also present
in 15–25% of corresponding sporadic tumors [14]. Research
has shown that the frequency of MSI is 60–100% in col-
orectal, endometrial, stomach, and uroepithelial cancers2 Pathology Research International
associated with LS [15–19]. MSI testing has therefore served
as the diagnostic screening method for LS.
3. Identiﬁcation of LynchSyndrome
A family history of cancer plays an important role in the
recognition of LS. Clinical criteria (Amsterdam I and II)
have served in identifying LS families for clinical or research
purposes [7, 8]. Amsterdam I criteria include the following:
(1) at least three relatives should have histologically veriﬁed
colorectal cancer, one of whom should be a ﬁrst-degree rel-
ative to the other two; (2) at least two successive generations
should be aﬀected; (3) colorectal cancer should be diagnosed
in one of the relatives under 50 years of age; (4) familial
adenomatous polyposis should be excluded [6]. In 1999,
the International Collaborative group on HNPCC intro-
ducednewselectioncriteria(AmsterdamcriteriaII)thatalso
included extracolonic cancers associated with LS [8].
Clinical criteria known as the Bethesda Guidelines have
been developed to enable identiﬁcation of colorectal tumors
inrelationtowhichmolecularanalysisshouldbeundertaken
[9, 10]. A patient who meets the Bethesda criteria may need
for molecular genetic studies either by MSI analysis of the
tumor or immunohistochemical analysis of the MMR pro-
teins. If a mutation is identiﬁed in the family, genetic coun-
selling and genetic testing should be organized for all at-risk
relatives. Such testing allows clinical screening to focus on
mutation carriers and to exclude noncarriers from repeated
examinations.
4. Tumor Spectrumof LynchSyndrome
CRC and endometrial cancer are the most prominent types
of cancer seen in LS [4]. However, several other cancer types
have been shown to occur more frequently in LS than in the
general population: cancers of the stomach as well as uro-
logical (uroepithelial and kidney), ovary, biliary tract, small
bowel, and brain tumors [5, 6]. Researchers have suggested
that cancer phenotypes associated with MLH1, MSH2,a n d
MSH6 gene mutations diﬀer. For example, Vasen et al. [20]
found a higher risk for extracolonic cancers in mutation
carriers of MSH2 than in those carriers of MLH1.
5. Colorectal Cancer
Colonic tumors are the most common tumors in LS, ac-
counting for approximately 60–70% of the total [21, 22].
Studies have reported that a lifetime risk for developing CRC
in mutation carriers is 70% at age 70 (range 30–80%) [5, 20,
23]. However, the estimation of risk seems to diﬀer depend-
ing on sex and type of mutation. A Finnish study [5]f o u n d
that the standardized incidence ratio for CRC was higher in
men (83) than in women (48), and the male-to-female ratio
was 1.7. The reason for the relatively low incidence of CRC
in women is unknown. Dunlop et al. [23] suggested that
women may be protected in some way because of environ-
mentalfactorsorevenasex-linkedmodiﬁergene.Thereisno
diﬀerence in CRC risk between MLH1 and MSH2 mutation
carriers. However, Hendriks et al. [24] observed that female
MSH6 mutation carriers are at signiﬁcantly lower risk for
CRC than are MLH1 and MSH2 mutation carriers.
Several clinical features typical of colonic tumors are
associated with this syndrome. They most often occur in the
proximal colon (60–70% in LS, 30% in sporadic CRC). CRC
occurs at younger ages in HNPCC (mean 40–45 years) than
in sporadic cases (mean 60–65 years), and mutation carriers
of HNPCC are at higher risk for multiple synchronous and
metachronous CRCs [21, 22].
Colorectal tumors in LS seem to evolve through the
adenoma-carcinoma sequence, as they do in sporadic CRC
[25]. In Ls, however, the adenomas occur in younger indi-
viduals and tend to be larger and more severely dysplastic
than in sporadic cases [26–29]. In addition, studies have
shown that adenomas in LS patients are located mainly in
the proximal colon [29, 30]. Most adenomas in mutation
carriers show MSI or the absence of immunohistochemical
staining of the MMR proteins [31]. For CRC in LS, studies
have reported MSI frequencies of 85–90% [16]. It has been
suggestedthethattheadenoma-carcinomasequenceisaccel-
erated in LS and that the progression from adenoma to car-
cinoma may take two to three years compared to eight to ten
yearsinthegeneralpopulation[32].Also,thehistopathology
of CRC in LS patients has some special features in com-
parison to CRC in general, as CRC is often mucinous and
poorly diﬀerentiated [26, 27]. Diploid tumors and singlet-
ring cancers also seem to be common in Lynch syndrome
[26, 33]; however, it should be noted that, although these
features are not speciﬁc to this syndrome, they could serve
as additional markers for its recognition.
Colonoscopic surveillance has been recommended for
mutationcarriersofLStopreventthedevelopmentofcancer.
J¨ arvinen et al. [11] conducted a long-term controlled study
comparing colonoscopic screening (three-year intervals)
with no screening of at-risk members of LS families. The
results showed that screening signiﬁcantly reduced the inci-
dence of CRC (6% in screened patients versus 16% in con-
trols)andinoverallmortality(8%inscreenedpatientsversus
22% in controls). Recently, a group of European experts
inhereditarygastrointestinalcancerrecommendedscreening
by colonoscopy for mutation carriers every one to two years
beginning at age 20 to 25 [34].
As mentioned above, mutation carriers of LS are at rel-
atively high risk for synchronous or metachronous tumors.
Therefore, researchers have suggested that total or subtotal
colectomy is the operation of choice in LS patients with col-
orectal tumors [35]. Others have discussed prophylactic co-
lectomy as a reasonable option in mutation carriers for
whom colonoscopy is painful or diﬃcult [36, 37]. In addi-
tion, prophylactic surgery may be the best treatment for a
patientwithseveraladenomasthatcannotberemovedendo-
scopically [36, 37]. Presently, however, prophylactic colec-
tomy remains controversial in the management of LS pa-
tients. Recent studies have reported that patients with CRC
from LS families survived longer than did sporadic CRC
patients with same-stage tumors [38, 39]. The reasons for
thefavorablesurvivalratewithCRCinthissyndromeremain
unclear. One explanation is that immunological host defense
mechanisms may be more active in tumors of the MSIPathology Research International 3
phenotype [40]. Also, it has been suggested that the relatively
high mutational load that occurs in tumors with defective
DNA repair systems is detrimental to their survival [41].
It has been suggested that nonsteroidal anti-inﬂamma-
tory drugs (NSAID) (e.g., aspirin) reduce the risk for CRC
[42, 43]. Recently, Burn et al. [44] reported their results of
the long-term eﬀect of aspirin on the incidence of CRC in
mutation carriers of LS. Their randomized study comprised
861 individuals with a mean follow-up time of 56 months.
Theauthorsshowedthat600mgaspirindailyclearlyreduced
the incidence of cancer in carriers of LS after 56-month
followup. The mechanisms by which aspirin prevents the
development of cancer are unknown, though some have
suggestedthataspirinmaybeproapoptoticintheearlystages
of CRC development [44].
6.EndometrialCancer
Endometrial cancer occurs at younger ages in LS patients
than in sporadic cases. The mean age at diagnosis is 49 years
compared to 60 years in the general population [45]. Studies
have reported that families with MSH6 mutations are at
higher risk for developing endometrial cancer (64–71%)
than MSH2 or MLH1 families (40–50%) [24, 46]. As in the
caseofsporadicendometrialcancer,themajorityofendome-
trial cancers in this syndrome are of the endometrial type
[47]. Studies have shown that there is no diﬀerence in out-
comes in endometrial cancer associated with LS compared to
those in sporadic cancer [48].
Regular surveillance for endometrial cancer has been
recommended for women with LS for the prevention or
earlydiagnosisofcancer[34].Somestudieshaveinvestigated
the eﬃcacy of gynecological surveillance in LS. In a study
by Dove-Edwin et al. [49], a study group consisted of 269
female LS family members in whom transvaginal ultrasound
was performed every one to two years. No asymptomatic
endometrial cancers were found, but two interval cancers
were diagnosed based on symptoms. Rijcken et al. [50]
presented the results of a gynecological screening pro-
gram in 41 mutation carriers. They found three patients
with premalignant lesions but no cases of asymptomatic
endometrial cancer. A study of 175 mutation carriers from
Finland reported the results of surveillance using transvagi-
nal ultrasound and aspiration biopsy [12]. Endometrial
cancer occurred in 14 cases, 11 of which were diagnosed
using surveillance. Of the 11 screen-detected cancers, 6
were identiﬁed using only aspiration biopsy and not using
ultrasound. The results also showed that stage distribu-
tion and survival were more favorable in the surveilled
patients than in the unsurveilled patients. According to a
study by Nieminen et al. [51], it seems that endometrial
carcinoma will develop gradually via complex hyperplasia,
and molecular genetics alternations can be observed years
before cancer. Based on the previous studies [12, 49, 50],
current surveillance guidelines for women with LS include
annual transvaginal ultrasound and endometrial sampling
starting at age 20 to 35 years. Prophylactic hysterectomy
and bilateral salpingo-oophorectomy are recommended for
female mutation carriers who are beyond childbearing age,
especially if surgery for colorectal cancer is needed [52].
7.GastricCancer
Gastric cancer is the second most common extracolonic ma-
lignancy in LS with a cumulative risk of 2% to 13% [5, 20,
53]. As in the case of colorectal and endometrial cancers,
gastric cancer in this syndrome occurs at an earlier age than
in the general population [54] .T h eo c c u r r e n c eo ft h i sc a r c i -
noma seems to be not diﬀerent between diﬀerent mutations.
Studies have shown that over 90% of gastric cancers in
LS are of the intestinal type and that tumors have a high
degree of MSI [54]. Generally, the diﬀu s et y p eo fc a n c e rp r e -
dominates in young patients and is the most common type
in the familial form of gastric cancer [55]. The development
of the intestinal type of gastric cancer is closely related to
Helicobacter pylori-associated chronic gastritis. Studies have
therefore suggested that H. pylori infection and atrophic
gastritis could serve as markers of increased risk for gastric
cancer in individuals with LS. A Finnish study, however,
reportedthatonly20%ofgastriccancersinLSwereH.Pylori
positive [54].
Renkonen-Sinisalo et al. [56] evaluated the value of
gastroscopic surveillance in a series of 73 mutation carriers.
In this study, no cases of early cancer or premalignant lesions
were detected during surveillance. A collaborative group
of European experts in hereditary gastrointestinal cancer
recommends screening for gastric cancer in LS families with
a clustering of stomach cancer and in countries with a high
prevalence of it [34]. It has been suggested that serological
biomarkers such as pepsinogen I and II as well as H. pylori
antibodies, could be a nonendoscopic screening method in
evaluating individual risk for gastric cancer in LS.
8.UroepithelialandKidney Cancers
Several epidemiological studies have shown that urothelial
(i.e., ureter and bladder) as well as kidney cancers are an
integral part of the LS tumor spectrum with a lifetime risk
of 1% to 12% [5, 6, 53]. Van der Post et al. [57]r e p o r t e da
clearly increased risk for bladder cancer, especially in MSH2
mutation carriers. Correspondingly, Watson et al. [6]f o u n d
that MSH2 mutation carriers were at a sevenfold higher
lifetimeriskforurologicaltumorsthanwereMLH1mutation
carriers.Ureterandbladdercancersoccurapproximately10–
15 years earlier than those in the general population [6, 57].
The histology of these urothelial tumors associated with
LS is similar to that of sporadic cases [57]. Studies have
reported high frequencies of MSI for urothelial tumors in
LSthatclearlyexceedfrequenciesforcorrespondingsporadic
tumors [19].
A higher risk for kidney adenocarcinomas has been
observed in a large series of LS families than in the general
population [5, 6]. MSI is seldom observed in kidney cancers,
however, and the median age of this cancer seems to be not
lower than that in sporadic cases [19]. Therefore, researchers
have suggested that kidney cancers may not be part of the
tumor spectrum of LS.4 Pathology Research International
Urine cytology has been shown to be insensitive in
screening for bladder and ureter cancers in LS mutation car-
riers[58].Ontheotherhand,Europeanexpertsinhereditary
gastrointestinal cancer recommend screening for urological
tumors using abdominal ultrasound, urinalysis, and urine
cytology [34]. Screening should start at age 30 to 35 years
with one- to two-year intervals [34]. This strategy is espe-
cially intended for families with clustering urological tumors
[34].
9. Other Tumors
9.1. Ovarian Cancer. Ovarian cancer has been shown to
occur in excess in LS. Two Finnish studies [5, 45] have shown
a lifetime risk for ovarian cancer in LS ranging between
9% and 12% compared to 1.3% in the general population.
Recently, Watson et al. [6] reported a lifetime risk of 7% in
a large series from four LS research centers. They also found
that MSH2 family members had nearly twice the incidence
rate observed in MLH1 family members, and the highest
risk period for ovarian cancer was from age 40 to 55 years.
Ovarian cancer in LS seems to have a better prognosis than
that in the general population or in BRCA1/2 mutation
carriers [59]. Information currently available is too limited
toassesswhetherscreeningforovariancancerinLSmutation
carriers has any advantages.
9.2. Carcinomas of the Biliary Tract and Pancreas. These
carcinomas seem to be associated with LS [60]. Estimates
indicate that a lifetime risk of these cancers is approximately
2% in mutation carriers of LS [5, 45]. Surveillance for pan-
creatic or biliary tract cancer is not regularly recommended
for family members with LS.
The lifetime risk for small bowel cancer associated with
LS has been estimated to range between 1% and 4% [20, 61].
Studies have also reported that LS-associated small bowel
canceroftenmanifestsatayoungageandmaybetheﬁrstdis-
ease manifestation [61, 62]. Tumors occur predominantly in
the duodenum or the jejunum [61, 62]. Screening for small
bowel cancer is not in the guidelines for clinical management
of family members with LS.
9.3. Brain Tumors. Brain tumors occur in excess in patients
with LS [63]. The estimated cumulative incidence of brain
t u m o rr a n g e sf r o m2 %t o4 %i nf a m i l ym e m b e r sw i t hL S
[5, 6]. Vasen et al. [53] reported that the risk for brain tumor
is higher in MSH2 than in MLH1 mutation carriers. It has
also been reported that brain tumors in LS are microsatellite
stable [19]. No studies have investigated surveillance for
b r a i nt u m o r si nL S .
10. Conclusions
Knowledge of the tumor spectrum in Lynch syndrome is
important in planning strategies for the management of
patients with this syndrome. Screening proved beneﬁcial
only for CRC and endometrial cancer although screening for
other tumors is also recommended. Family history is an
important tool for identifying LS. Clinical criteria serve to
select suspected cases for molecular studies, such as MSI
analysis of the tumors or immunohistochemical analysis of
the MMR proteins. It is now possible to undertake predictive
genetic testing in family members once a mutation has
been detected in a family. However, it is important to orga-
nize genetic counselling individually before genetic testing.
Genetic testing allows clinical screening to target mutation
carriers while excluding mutation-negative individuals from
further examination.
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